Healthcare / BiotechnologyTokyo
$54.00
+2.00 (+3.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-1.2B · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-124.5%
↓Gross Margin
97.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-58.1%
FCF CAGR
—
FCF margin
-110479.2%
FCF / Net income
1.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.1M · net income $-1.15B · FCF $-1.25B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1M | $1.1M | $72000.00 | $5.3M | $15.4M |
| Net Income | $-1.15B | $-1.15B | $-1.17B | $-1.49B | $-1.48B |
| EBITDA | $-1.16B | $-1.16B | $-1.15B | $-1.47B | $-1.45B |
| EPS | -14.12 | -14.12 | -18.21 | -24.90 | -28.55 |
| Gross Margin | 97.2% | 97.2% | 75.0% | 64.1% | 78.5% |
| Operating Margin | -102464.1% | -102464.1% | -1604276.4% | -27785.2% | -9579.7% |
| Net Margin | -101601.9% | -101601.9% | -1622336.1% | -28137.0% | -9632.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.11 | — | 0.03 |
| Current Ratio | 7.09 | 7.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.25B | $-1.25B | $-1.16B | $-1.21B | $-1.53B |
| Returns | |||||
| ROE | -124.5% | -124.5% | -119.3% | -94.8% | -58.6% |
| Valuation | |||||
| P/B | 4.76 | 4.76 | 4.06 | 5.86 | 2.14 |
| Growth & Yield | |||||
| Revenue Growth | 1473.6% | 1473.6% | -98.6% | -65.7% | — |
| EPS Growth | 22.5% | 22.5% | 26.9% | 12.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+35.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-18.21 → -14.12
Residual
+35.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.